Get notified when NGNE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNeurogene completes dosing in pivotal Rett syndrome gene therapy trial
Filed June 8, 2026 · Period ending June 8, 2026 · ~1 min read
Key Changes
-
high
Neurogene finished administering NGN-401 to all patients in its EmboldenTM registrational trial for Rett syndrome, a critical milestone moving the gene therapy candidate closer to potential regulatory submission.
Item 8.01 view on EDGAR → -
medium
The company posted an updated corporate presentation on its website, likely reflecting the trial milestone and providing strategic context for investors.
Item 8.01 view on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (THRM 10-Q) is open in full — no account needed.
Partner
Trade NGNE commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify